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ABSTRACT Maurizio Vignola was a superb and innovative researcher, who wrote seminal papers on the
biology of airway epithelium in asthma. Inflammation and remodelling were the main topics of his research,
mostly conducted in biopsy specimens from patients with asthma of variable severity, encompassing the
entire spectrum of the disease from mild to severe asthma. His observations contributed to define the
biology of asthma as we know it today, and opened the way to the personalised treatment of asthma. His
group has successfully continued to investigate the biology and clinical aspects of bronchial asthma, with
major interest in the clinical use of biomarkers to monitor disease activity, and in the development of new
therapeutic perspectives. This review summarises the latest work on these topics proudly conducted by
Maurizio’s closest collaborators. The results indicate significant progress in our understanding of asthma in
the last 10 years, in particular increased knowledge of the complex interaction between inflammatory and
remodelling pathways, improved recognition of biological and clinical asthma phenotypes, and development
of new treatment strategies, especially for patients with severe corticosteroid-resistant asthma.
@ERSpublications
Biomarkers may help to define disease phenotypes and new treatment strategies for asthma
http://ow.ly/G2Fl6
Introduction
The life of Maurizio Vignola (fig. 1) was too short, but was sufficient to leave durable signs in the
development of a new paradigm for bronchial asthma. Since his first days as a research fellow, first in
Montpellier, France, under the guidance of Jean Bousquet, then in Omaha, NE, USA, with Stephen
Rennard, he showed innovative thinking and exceptional scientific maturity, a really uncommon finding at
his young age. Lifelong friendship and fruitful collaboration were also established in those days with Pascal
Chanez, who continued to collaborate with the research group in Palermo, Italy.
Maurizio was very interested in the biology of airway epithelium, and his studies on biopsy specimens
from patients with asthma of variable severity allowed him to understand some aspects of the disease that
had not been studied in depth. He used immunohistochemistry, a relatively “primitive” technique
compared with the sophisticated methods used today, to study several markers of epithelial damage,
inflammation, apoptosis, regeneration and remodelling [1–5], which allowed him to propose a new, more
complex model of asthma, especially in its most severe form [6]. He addressed the pathogenesis of
resistance to corticosteroid treatment [2, 7–9], and also studied the complex relationship between asthma
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and chronic obstructive pulmonary disease (COPD) when they coexist in the same patient [10]. His
research soon extended to extracellular matrix, and he published seminal papers on the role of
transforming growth factor (TGF)-β [11] and tissue metalloproteinases in asthma [12], setting a new
paradigm of the disease that still stands today. He also realised that paediatric asthma could be used to
study the earliest aspects of the disease, without the confounding effect of environmental exposures
commonly found in adult patients [13]. Finally, he explored the dynamic nature of airway remodelling and
the role of myofibroblasts in this process [14].
Space constraints do not allow a thorough discussion of all his scientific papers. Instead, this review
focuses on the results obtained in the last few years by his group, who kept working on asthma, first by
continuing research on the biology of asthmatic epithelium and on the interactions between upper and
lower airway inflammation, and secondly by testing the results obtained through experimental studies in
asthmatic patients.
Airway inflammation and remodelling
Asthma is an inflammatory disorder of the airways, characterised by infiltration of mast cells, eosinophils
and T-helper cell type 2 (Th2) CD4+ T-lymphocytes in the airway wall [15]. Eosinophils within the airways
of asthmatics: 1) are recruited via a chemical gradient due to the release of chemotactic agents (interleukin
(IL)-5 and eotaxin), 2) show a prolonged survival, and 3) induce epithelial damage and remodelling via the
release of eosinophil toxic products (eosinophil peroxidase and the eosinophil cationic protein).
Similarly, the accumulation of T-lymphocytes within the airways of asthmatics may be due to both
increased recruitment and decreased cell apoptosis [16]. The increased recruitment of lymphocytes may be
promoted by the release of lymphokines including thymic stromal lymphopoietin (TSLP) [17]. TSLP is
expressed by structural and immune cells at the site of allergen entry into the airways and has been
identified as a master switch for allergic inflammation, since it regulates and drives Th2 responses [18].
Th2 lymphocytes induce and regulatory T-cells (Treg) (characterised by Foxp3 expression) suppress
several features of allergic inflammation in asthmatics [15].
The Th2 response, and in particular increased expression of IL-13 within the lungs of asthmatic subjects,
triggers an aberrant injury-repair mechanism leading to remodelling of the airway wall. Some of the most
prominent effects of IL-13 include increases in goblet cell differentiation, activation of fibroblasts and
increases in bronchial responsiveness. Moreover, IL-13 induces bronchial epithelial cells to secrete
periostin, which in turn enhances profibrotic TGF-β, a tissue growth factor whose dysregulation is
associated with airway remodelling and might affect disease chronicity and severity [19].
FIGURE 1 Maurizio Vignola (1964–
2004).
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Airway epithelium is one of the principal actors in the pathological events associated with both bronchial
inflammation and remodelling in asthma [20]. Airway epithelium represents more than a protective
barrier against external insults, since it actively secretes pro-inflammatory mediators, i.e. leukotrienes and
cytokines such as IL-8 and TSLP, which in turn amplify the initial inflammation due to external insults by
recruiting and activating neutrophils in the early phase, and eosinophils and lymphocytes during the late
response. Bronchial epithelial cells are activated by cysteinyl leukotrienes including leukotriene (LT)D4, via
activation of extracellular signal-regulated kinase (ERK) 1/2 and of the signal transducer and activator of
transcription (STAT)-1, increasing their adhesiveness to eosinophils [21].
Studies on bronchial biopsies demonstrated that in asthmatics, especially if severe, the airway epithelium
highly expresses pro-inflammatory transcription factors including nuclear factor (NF)-κB [2] and cAMP
response element binding protein (CREB) [22]. Both transcription factors induce acetylation of chromatin
and transcription of pro-inflammatory genes, leading to persistent inflammation and severe disease.
The increased expression of phosphorylated (p)CREB in the airway epithelium is positively correlated with
leukocyte infiltration within the bronchi (CD45RB+ cells), strongly supporting the concept that activation of
the airway epithelium is crucial in the recruitment and activation of leukocytes within the airways, as
confirmed by the elevated expression of pCREB also in these cells [22]. Furthermore, increased pCREB
expression was also observed in peripheral blood mononuclear cells (PBMCs) from untreated and severe
asthmatics, suggesting that some of the molecular events crucially involved in the pathogenesis of asthma may
be evaluated in systemic compartments, thus avoiding bronchial biopsies to monitor asthma inflammation.
As a further support to the assessment of systemic inflammation to manage asthmatics, it has been shown
that IκB kinase (IKK), a complex tightly regulating NF-κB activation, and in particular IKKβ activity, was
higher in PBMCs in asthmatic patients than in controls [23]. IKKβ activation seems to be specific for
asthma, since increased IKKα activity was found in patients with COPD and healthy smokers compared
with asthmatic patients or controls [23]. The different profile in the upstream regulation of the IKK-driven
NF-κB system in asthmatic and in COPD patients may explain, at least in part, the different
pro-inflammatory and pharmacological responses in asthmatic versus COPD patients.
Persistence of chronic inflammation may alter the homeostasis of lung tissue, leading to airway remodelling.
Tissue remodelling includes epithelial alterations (epithelial shedding), increased matrix deposition, matrix
degradation and accumulation of plasma proteins. Genetic influences, fetal exposures and early life events,
and long-term uncontrolled inflammation may all contribute to airway remodelling. Structural changes may
alter the protective functions of the airways by affecting mucociliary clearance and increasing the risk of
infections and/or exacerbations. Furthermore, activated fibroblasts and smooth muscle cells may release
pro-inflammatory mediators, leading to amplification of subsequent tissue damage [24].
The adipokine leptin is a potential new player in bronchial epithelial homeostasis, since it counteracts
some molecular events crucially involved in airway remodelling [25]. Leptin decreases the spontaneous
release of TGF-β and promotes tissue repair by increasing epithelial cell proliferation. Conversely, TGF-β
decreases leptin receptor expression in the airway epithelium. The bronchial epithelium of asthmatics
undergoes shedding, and shows decreased expression of leptin and its receptor, increased thickness of the
reticular basement membrane and increased TGF-β expression compared with the values found in healthy
volunteers [26].
Biomarkers
Allergic diseases, including allergic rhinitis and asthma, are chronic inflammatory disorders with a
prevailing Th2 immune response. Inhalation of allergens leads to bronchial hyperreactivity and
recruitment of eosinophils, mast cells and lymphocytes in the upper and lower airways, triggering the
inflammatory cascade and generating local and systemic inflammatory responses. Uncontrolled
inflammation in the upper and lower airways and in the systemic circulation may compromise the control
of allergic rhinitis and asthma, with subsequent disease progression [27]. Therefore, from a clinical point
of view, it is important to detect and monitor the occurrence of inflammation and remodelling in the
upper and lower airways and in the systemic circulation of patients with asthma and allergic rhinitis. This
goal may be achieved using noninvasive methods such as induced sputum, exhaled breath condensate
(EBC), nasal wash and collection of blood samples. This approach might also be useful to characterise
different inflammatory phenotypes and monitor them in order to provide “personalised” treatment to each
individual patient.
Exhaled nitric oxide fraction (FeNO) measurements and collection of EBC are noninvasive techniques for
the assessment of nasal and oral airway inflammation in atopic subjects with and without asthma [28],
providing useful clinical information even in the absence of symptoms. In children with atopic dermatitis,
allergic rhinitis and asthma, FeNO, and pH and IL-5 levels in the EBC from upper and lower airways were
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studied to identify children with atopic disorders who might develop bronchial asthma, and to predict the
development of exacerbations in asthmatic children [29].
A large number of molecules measured in EBC, including LTB4, prostaglandin E2 and 8-isoprostane, are
considered useful markers of airway inflammation and oxidative stress in the airways. In children with
persistent rhinitis and asthma of variable severity, such markers and FeNO were measurable in both upper
and lower airways, but showed a large variability. Correlations between these markers and their persistence
despite treatment might help to identify a relationship between biomarkers in the two airway
compartments that might be useful to phenotype the “united allergic disease of the airways” [30].
In asthma, symptoms are often not specific and do not closely reflect the presence or severity of airway
inflammation [31]. GAGLIARDO et al. [32] showed that several biomarkers in induced sputum, including IL-8,
matrix metalloproteinase (MMP)-9, tissue inhibitor of metalloproteinase (TIMP)-1 and number of
eosinophils, as well as the levels of FeNO, were higher in children with intermittent asthma and moderate
asthma compared with healthy subjects, suggesting that the inflammatory process is associated with biological
and clinical heterogeneity. TGF-β1 in induced sputum supernatants was also higher in children with
intermittent or moderate asthma compared with controls, and was associated with activation of the
intracellular TGF-β/Smad signalling pathway in induced sputum cells. Therefore, a dynamic mechanism
results from the interaction between TGF-β1 signalling activity and inflammatory cells through the
commitment of bronchial epithelium, indicating a putative immunoregulatory role of TGF-β1 in the
progression of airway inflammation in paediatric asthma. As a consequence, treatment strategies should be
aimed at controlling inflammation and preventing airway structural changes in young asthmatic patients [33].
Recent studies have identified an IL-23-dependent T-cell population, a Th lineage distinct from Th1 and
Th2 called Th17, which plays an important role in inflammation and tissue injury [34]. Th17+ cells
primarily produce IL-17A, and include CD4+ and CD8+ T-cells showing either the Th1 or Th2 cytokine
profile [35]. IL-17+ cells are overexpressed in the lung during acute neutrophilic inflammation and asthma
[36]. In mouse models of airway inflammation, such as those driven by house dust mite allergen,
ovalbumin [37, 38] or ozone [39], IL-17A controlled bronchial hyperresponsiveness and airway remodelling
but did not affect airway eosinophilia and Th2 cell recruitment to the airways [40, 41]. These studies
suggest that some of the pathogenic effects of IL-17 are mediated directly on bronchial smooth muscle cells
and local fibroblast progenitors, rather than indicating a major effect on airway inflammation. At variance
with these experimental results, ALBANO et al. [42], using noninvasive methods (induced sputum, nasal
wash and plasma samples), showed that increased levels of IL-17A are involved in the systemic and upper
and lower airway inflammation in children with allergic asthma and rhinitis. In particular, higher levels of
IL-17A were documented in nasal wash and induced sputum supernatants of allergic children. In vitro,
IL-17A increased the production of IL-8 in nasal and bronchial epithelial cell lines. Moreover, increased
levels of intracellular IL-17A and RAR-related orphan receptor (ROR)Ct, associated with lower levels of
Foxp3 in T-lymphocytes, together with higher plasma levels of IL-17A, suggest a Th17/Treg imbalance in
moderate forms of allergic asthma and rhinitis. Therefore, Th17 immunity appears to be involved in allergic
asthma and rhinitis in children, reinforcing the concept of the “united airway disease” in allergic diseases
[42]. Despite the progress in our understanding of the pathophysiological functions of Th17 cells in
inflammatory diseases of the airways, the regulation of Th17 responses remains relatively poorly understood
and controversial. Research on the regulation of Th17 responses in airway disease is quite limited, and the
underlying mechanisms have not been thoroughly studied. However, altogether the available studies
indicate that the Th17 responses may be differently regulated under in vitro or ex vivo conditions, in animal
or human models, in different cell types, or according to variable patterns of endogenous molecules, drugs,
steroids or bacterial products in the setting of inflammatory disease [43].
Nebulisers are still frequently used in clinical practice to overcome problems with the technique of inhalers
[44], and nebulisation is particularly useful to deliver bronchodilators in children, the elderly and severe or
steroid-dependent asthmatics [45]. PROFITA et al. [46] conducted a randomised, double-blind, placebo-
controlled study to determine whether nebulised beclomethasone dipropionate (nBDP) may positively affect
inflammation and improve the clinical and functional status in children with both allergic asthma and
allergic rhinitis with exclusive exacerbation during the pollen season. nBDP (400 g twice a day for 4 weeks)
was administered through a facial mask, looking at specific markers of inflammation from the nose and
bronchi during the season of allergen exposure. Treatment with nBDP reduced the levels of oral FeNO and
oral EBC IL-5, while it did not affect the levels of oral pH. In the nasal compartment, nBDP reduced the
levels of EBC IL-5 and increased EBC pH, while it did not affect FeNO. Therefore, noninvasive techniques
are very useful to study and monitor the effects of treatment, especially in paediatric asthma [46].
Recent studies have also examined the role of vitamin D in allergic diseases. Vitamin D is a potent immune
system modulator involved in the development of allergy-associated Th2 cells [47]. BONANNO et al. [48]
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investigated the relationship between different plasma levels of 25-hydroxyvitamin D (25(OH)D) in
children with allergic disease of the airways. Children with concomitant asthma and rhinitis who showed
deficient 25(OH)D had higher levels of blood eosinophils, a higher number of exacerbations in the last
year, a longer disease duration and higher total allergen IgE score and total atopy index compared with
children with normal 25(OH)D levels. Therefore, low levels of 25(OH)D in plasma samples could be useful
to identify children with allergic rhinitis prone to develop asthma [48].
Stepping forward from the Maurizio Vignola experience, the components of his group are still involved in
studies on noninvasive biomarkers of inflammation and remodelling in allergic disease. Together, these
studies have contributed to defining the phenotype of disease and to identifying the benefits of a
pharmacological approach in the control of the innate and adaptive immunity, and of the related
symptoms, in patients with allergic disease of the airways.
Asthma phenotypes and disease control: a new perspective
In the attempt to better characterise and treat bronchial asthma, several studies have been performed over
the last decade to define asthma phenotypes. A variety of parameters have been identified for this
definition: functional parameters, frequency of exacerbations, age of patients, presence of allergy,
geographical localisation [49] and biomarkers. In a recent pan-European study, the stability of phenotypes
in adults with controlled and severe asthma has been analysed in the BIOAIR cohort (longitudinal
assessment of clinical course and BIOmarkers in severe chronic AIRway disease study), to compare
phenotypes defined either by biomarkers (the “Hastie approach”) or by physiological variables (the
“Moore approach”) over 1 year of observation [50]. There are still conflicting data on the repeatability of
inflammatory phenotypes defined by sputum analysis. FLEMING et al. [51] found that sputum results were
unstable in children with asthma, whereas studies in adults suggested reasonable stability and repeatability
of sputum measurements [52, 53]. This BIOAIR study concluded that the inflammatory phenotypes
determined by induced sputum cellularity were less stable than those defined by physiological variables,
confirming that asthma is a variable inflammatory disease and, therefore, phenotyping to understand
mechanisms of the disease needs to be long-term and based on repeated measures, and should ideally
integrate several different outcomes [54].
On the basis of these considerations, it is necessary to define what we mean by “asthma control”. The
most used definition refers to the stability of clinical and functional parameters. A patient with normal
spirometry and no symptoms is generally defined as a “controlled” patient. However, some recent papers
have shown that the inflammatory profile of an asthmatic patient should also be taken into account in the
definition of asthma control. In this regard, within populations of patients with allergic rhinitis,
intermittent asthma (treated only with short-acting β2-agonists (SABA) on demand) or moderate asthma
(treated with inhaled corticosteroids (ICS) and long-acting β2-agonists plus SABA on demand), and also
within a population of patients with atopic dermatitis, some subjects show ongoing bronchial
inflammation, i.e. low pH and high IL-5 concentrations in the EBC, as well as increased FeNO levels [29].
Therefore, some specific “phenotypes” of these patient populations show evidence of bronchial
inflammation. Although these patients were not treated with ICS because they did not have bronchial
asthma (i.e. atopic dermatitis or rhinitis) or had intermittent asthma, they were probably representing a
specific phenotype of patients who may develop symptoms on an accelerated “allergic march”. Moreover,
within the group of patients with moderate asthma, who were treated with ICS, some of them displayed
bronchial inflammation according to the above-mentioned biomarkers, suggesting that these patients
might have been candidate to “step up” in the classification of their disease [29]. Accordingly, within a
population of patients with intermittent asthma, some subjects displayed increased expression of pCREB
and its receptor expression [22], and low expression of leptin and its receptor [26] in bronchial epithelium,
suggesting that in these patients bronchial inflammation occurs and can be demonstrated at the tissue
level. These latter studies also demonstrate that bronchial tissue inflammation occurs in some patients with
moderate asthma treated with ICS, suggesting that “specific phenotypes” of not fully controlled
inflammation do occur in patients.
Partially or not controlled disease, as indicated by positive biomarkers of inflammation in asthma, may
have important consequences on treatment. The longitudinal study conducted in paediatric patients with
asthma discussed earlier [32] confirmed that a specific phenotype of controlled disease on the basis of
symptoms and spirometry, with increased bronchial inflammation on the basis of inflammatory
biomarkers, is associated with poorly controlled disease and frequent exacerbations.
As already mentioned, the involvement of the upper airways strongly influences the control of bronchial
asthma both from a functional and an inflammatory point of view. In a pan-European study conducted by
the Global Allergy and Asthma European Network (GA2LEN), chronic rhinosinusitis was positively
associated with adult-onset asthma. This association has been interpreted as chronic rhinosinusitis causing
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asthma, because of the release of inflammatory mediators and cytokines from the diseased sinus tissue into
the circulation and recruitment of eosinophils into both upper and lower airways from the bone marrow
and circulation [55]. These observations confirm that patients with asthma and chronic rhinosinusitis
represent a phenotype where upper airway inflammation has to be controlled to achieve a complete
control of asthma. Chronic rhinosinusitis and asthma are linked by a common inflammatory pathway, in
which eosinophils and airway epithelium play an important role [56, 57]. Many asthmatic patients,
whatever their severity, have chronic rhinosinusitis demonstrated on computed tomography scans. Patients
with severe asthma, uncontrolled asthma or both have more severe computed tomography scan
abnormalities than other patients. In many patients with severe asthma, surgical treatment of chronic
rhinosinusitis or nasal polyposis might improve asthma symptoms [57]. Accordingly, a recent study from
our group used an asthma-specific gene array to assess the inflammatory profile of nasal biopsies from
patients with chronic rhinosinusitis and nasal polyps [58]. Among the cytokines whose expression was
altered, IL-19, a cytokine contributing to the increased activation of Th2 lymphocytes, was increased in
patients with chronic rhinosinusitis with nasal polyps [58]. Moreover, IL-19 protein was found to be
highly expressed in the metaplastic nasal epithelium when compared with normal or hyperplastic
epithelium [58]. IL-19 could therefore contribute to the increased proliferation of nasal epithelial cells and
to remodelling processes in these patients.
Phenotyping patients with bronchial asthma represents an important strategy to achieve control of this
complex disease. Future therapeutic strategies will certainly take into account the characterisation of these
“phenotypes” made on the basis of the predominant pathogenetic pathway(s) of inflammatory processes.
Mechanisms in glucocorticoid control of inflammation
Glucocorticosteroids are widely used to treat various inflammatory and immune diseases. The most
common use of glucocorticosteroids today is in the treatment of asthma and other allergic diseases, and
inhaled glucocorticosteroids have now become established as a first-line treatment in adults and children
who have persistent asthma. Suppression of inflammation by corticosteroids positively affects asthma
symptoms and airway inflammation in most patients. The major action of glucocorticosteroids is to switch
off activated inflammatory genes that encode for cytokines, chemokines, adhesion molecule, inflammatory
enzymes and receptors [59].
Several studies have examined the efficacy of glucocorticosteroid-based therapies in airway inflammation,
cell activation and immunological responses. PACE et al. [60] showed that treatment with budesonide was
effective in controlling asthma inflammation by reducing both T-lymphocyte activation and survival and
inducible T-cell co-stimulator (ICOS) in CD4+/CD25− cells, and by increasing survival and activation of
CD4+/CD25+Foxp3+ cells (Treg) both in vitro and in vivo. Furthermore, fluticasone propionate was shown
to control peripheral blood T-cell activation and induce T-cell apoptosis through activation of caspases 8
and 3 in mild-persistent asthmatics [61]. VIGNOLA et al. [62] showed that in mild-persistent asthmatics,
low-dose fluticasone propionate was effective in improving symptoms due, at least in part, to the resolution
of eosinophilic bronchial inflammation and downregulation of remodelling markers, such as MMP-9 and
TIMP-1 levels in induced sputum samples. Other in vitro studies confirmed these findings: flunisolide
treatment of sputum cells isolated from asthmatic subjects with mild-to-moderate asthma inhibited the
release of MMP-9, TIMP-1, TGF-β and ﬁbronectin and increased eosinophil apoptosis [63]. Exposure of
induced sputum cells from mild to moderate asthmatic subjects to beclomethasone dipropionate reduced
granulocyte-macrophage colony-stimulating factor, RANTES and IL-8 levels and induced transcription of
the β2 receptor [64]. Furthermore fluticasone furoate is able to upregulate the leptin/leptin receptor
pathway also in nasal epithelial cells, thus increasing epithelial homeostasis upon allergen exposure [65].
Understanding molecular mechanisms whereby corticosteroids suppress inflammation explains how
glucocorticosteroids are able to inhibit inflammatory pathways, and also provides insights into the complex
molecular mechanisms of steroid unresponsiveness. glucocorticosteroids activate and suppress many pro-
and anti-inflammatory genes, such as NF-κB and correlated kinase proteins [59]. Several distinct
molecular mechanisms contributing to decreased anti-inflammatory effects of glucocorticosteroids have
been identified. Excessive activation of NF-κB can cause reduced or absent responsiveness to
glucocorticoids in asthma, since NF-κB binds the glucocorticoid receptor, preventing its interaction with
the glucocorticoid response element and other transcription factors. PBMCs from uncontrolled severe
adult asthmatics showed higher levels of NF-κB p65 protein expression, IκBα phosphorylation and IKKβ
kinase activity than normal individuals, despite long-term inhaled and oral glucocorticosteroid treatment
[9, 23]. A similar state of overexpression and activation of NF-κB p65 subunit protein in PBMCs and
induced sputum cells has been shown in children with moderate to severe asthma [13, 32].
Activated glucocorticoid receptor interacts with co-repressor molecules to attenuate NF-κB-associated
co-activator activity, thus reducing histone acetylation and chromatin remodelling. Chromatin modiﬁcation
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plays a critical role in the regulation of inflammatory genes and there is an extensive literature concerning
histone acetylation and mechanism of action of glucocorticosteroids. CHIAPPARA et al. [22] showed that the
increased expression of pCREB can be modulated by glucocorticoids in responsive asthmatic patients.
Stepping forward from the Maurizio Vignola experience, our research group has further contributed to the
definition of the molecular mechanisms in glucocorticoid control of inflammation. The new insights into
corticosteroid action may lead to new pharmacological approaches to treat inflammatory lung diseases,
and in particular to counteraction of reduced steroid responsiveness in complex inflammatory diseases,
such as asthma.
New therapies in corticosteroid-resistant asthma
Since multiple asthma phenotypes with distinct pathogenetic profiles have been identified, a personalised
strategy in treatment directed towards disease-specific features is expected to improve outcomes in these
specific patients [66].
Allergic asthma is characterised by increased levels of IgE. Omalizumab, a humanised anti-IgE monoclonal
antibody specifically binding free IgE, has been introduced in asthma treatment. Omalizumab interrupts
the allergic cascade by preventing the binding of IgE with its high-affinity FcεRI receptors on target cells
(mast cells, basophils, antigen-presenting cells, etc.) [67]. Its clinical efficacy has been well documented in
a number of clinical trials in patients with moderate-to-severe and severe allergic asthma and with
increased levels of IgE. Omalizumab reduced exacerbations, asthma symptoms and use of ICS and rescue
medication, and improved quality of life relative to placebo [68]. Results from recent pooled data from
randomised clinical trials and from a large prospective cohort study provided reassurance about the
long-term safety of omalizumab. Long-term treatment with omalizumab was able to reduce inflammation
[69] and improved clinical control in severe asthmatics [70]. In severe uncontrolled asthma, omalizumab
increased Foxp3 expression and decreased the pCREB/CREB ratio and IL-8 expression. These findings
correlated with the forced expiratory volume in 1 s (FEV1) values and symptom scores [70].
Another asthma phenotype is characterised by increased numbers of neutrophils in the airways of a
subgroup of patients with severe asthma, characterised by inadequate symptom control and high rate of
inflammation despite high doses of steroids. Since IL-8, a neutrophil chemotactic agent, exerts
pro-inflammatory responses in leukocytes by activating the G-protein coupled receptor CXCR2, a selective
CXCR2 receptor antagonist (SCH 527123) was tested in a randomised clinical study in patients with
severe asthma and increased number of neutrophils in sputum. A mean reduction of 36.3% in sputum
neutrophil percentage was shown in the treated arm, compared with a 6.7% increase in the placebo arm.
In addition, asthmatics treated with SCH 527123 experienced fewer mild exacerbations without additional
adverse events compared with the placebo group [71]. Conversely, a randomised clinical study on the use
of golimumab (50, 100 or 200 mg), a human monoclonal antibody against tumour necrosis factor
(TNF)-α, did not demonstrate a favourable risk–benefit profile in patients with severe persistent asthma
[72]. Golimumab-treated asthmatics experienced major adverse events, including serious infections,
without any advantage in terms of asthma control or improved FEV1. The potential use of anti-TNF
monoclonal antibodies in asthmatics remains undefined, since this study showed inaccurate selection of
severe asthmatics, i.e. patients were not selected based on elevated levels of TNF before treatment.
To further underline the need for accurate phenotyping of asthmatic patients, a recent clinical trial using the
anti-IL-13 lebrikizumab demonstrated that patients with high pre-treatment levels of serum periostin had
greater improvement in lung function with lebrikizumab than did patients with low periostin levels [73].
New advanced biotechnologies may provide further perspectives in the therapy of severe asthma by
re-directing the immune and inflammatory responses in these patients. In this regard, synthetic
hypoallergenic fragments of Parietaria judaica upregulated innate immunity receptors and increased
interferon-γ, and appeared capable of re-orienting the immune system towards a more physiological
balance between Th1 and Th2 responses [74]. In summary, personalised therapy aimed at targeting
disease-specific features will allow better control in asthmatics, but further studies are still needed to
achieve this important goal.
Finally, nonpharmacological therapeutic approaches could also be useful in asthma treatment. Physical
exercise has been shown, in animal models of allergic asthma, to significantly reduce airway inflammation
[75]. In healthy humans, studies on induced sputum cells at rest and after a marathon [76] or
half-marathon [77] race documented that intense exercise caused mild epithelial injury and influx of
neutrophils into the airways, possibly due to hyperosmolarity of the airway lining fluid secondary to the
hyperpnoea of exercise. However, no significant activation of inflammatory cells occurred [76, 77], in line
with the anti-inflammatory effects of exercise documented in animal models. However, such inflammation
could negatively affect airway muscle tone. Subsequent studies in healthy runners showed that trained
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subjects were less responsive to single-dose methacholine inhaled in the absence of deep breaths [78],
suggesting a positive effect of repeated airway smooth muscle stretching during exercise hyperpnoea.
Moreover, healthy sedentary subjects showed decreased bronchial responsiveness after 12 weeks of training
[79], and the same effect occurred in sedentary subjects with mild asthma undergoing the same training
protocol [80]. Similar results of decreased bronchial responsiveness have been recently reported after
application of continuous positive airway pressure (CPAP) during sleep for a week in asthmatic patients
free from sleep disordered breathing [81]. Population studies also documented an inverse relationship
between physical activity and bronchial responsiveness [82]. Therefore, exercise training might be
beneficial in asthmatics, and mechanical stretch of the airways is a possible mechanism of the beneficial
effects of exercise or CPAP. However, more data are needed before these results can be applied clinically.
Conclusion
Maurizio Vignola enthusiastically set up a solid research group that in the last 10 years has carried forward
the large amount of work that he had so successfully started. Research activity has continued on both the
experimental and the clinical aspects of asthma, with special regard to the biology of inflammation and
remodelling of the airways, the relationship between upper and lower airway inflammation, and the
complex mechanisms responsible for steroid-resistant asthma. On the clinical side, the group is part of
European networks and actively contributes to the studies on the definition of asthma phenotypes based
on biomarkers. Finally, studies on new treatment strategies will help to achieve the personalised treatment
of asthma that Maurizio Vignola had foreseen as “the future” for asthma patients.
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